Georgia Bio Becomes Georgia Life Sciences

Georgia Bio Becomes Georgia Life Sciences

Rebrand reflects organization’s growth state and key expansion of the sector


FOR IMMEDIATE RELEASE


Atlanta, GA (January 22, 2025) – Georgia Bio announced that it has rebranded the organization as Georgia Life Sciences, bringing renewed focus and support to the core strengths of the business and academic organizations within Georgia’s life sciences and healthcare communities.


As the leading advocate for the state’s dynamic and diverse life sciences sector, Georgia Life Sciences promotes policy development, community programs, industry initiatives, and events, as well as the research and products of its associated member and partner organizations.


“This is a key milestone for the association. Our rapidly growing membership is a testament to the strength of our community," said Maria Thacker-Goethe, President and CEO, Georgia Life Sciences. “We recognized that our association's brand should reflect and amplify the essence of our organization and project the impact of our success on behalf of our members. As we determined that a refresh to our visual branding was needed, it became evident that our naming convention no longer reflected our mission in serving Georgia’s expansive and growing life sciences sector.”


Georgia Life Sciences will maintain their established leadership role as a convenor in Georgia by continuing to advocate for effective national, state and local policies that protect and preserve innovation, attract public and private partnerships, improve educational opportunities, and promote the renowned research institutions and cutting-edge technological resources that has established the state as a viable leader in life sciences innovation.


Georgia Life Sciences supports its membership through several organizational areas of focus:

  • Policy & Advocacy: Advance life sciences innovation through policy and advocacy leadership at all levels of government
  • Workforce & Talent: Establish Georgia as a center for excellence in life science workforce training and talent development
  • Economic Development: Provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in Georgia
  • Innovation and Entrepreneurship: Serve as catalyst for life sciences innovation by helping entrepreneurs build successful ventures, access capital, and identify non-dilutive funding opportunities
  • Networking and Collaboration: Foster connection by convening thought leaders around relevant industry topics and peer-to-peer exchange
  • Cost Savings: Curated discounts on products and services critical to running a successful business


# # #

About Georgia Life Sciences

Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at www.galifesciences.org.


CONTACT:

Stacey Bowlin

Georgia Life Sciences

sbowlin@galifesciences.org

703-402-7608

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS